FIELD: lipids; pharmaceuticals.
SUBSTANCE: present invention relates to a method for producing a lipid mixture, comprising preparing an alcoholic solution of phosphatidylcholine and a solution of alpha-tocopherol and cholesterol in chloroform, mixing these solutions and removing chloroform under vacuum, while to remove alcohol and chloroform residues from the lipid mixture, said mixture is lyophilized in the presence of purified water placed in open containers separately from the alcohol solution of the lipid mixture on the shelves of the sublimation chamber, and the ratio of the volume of alcohol to the volume of water is at least 1 : 2, with the receipt after the end of the lyophilization process of a solid lipid mixture with a residual amount of organic solvents: chloroform - less 0.5 ppm., Ethanol - less than 0.3 ppm. The present invention also relates to a liposomal oral antiviral prophylactic agent.
EFFECT: technical result of the proposed invention is to increase the shelf life of the liposomal dosage form, in which the activity of alpha-interferon remains at a constant level for up to 42 months.
2 cl, 4 ex, 1 tbl, 1 dwg
Title | Year | Author | Number |
---|---|---|---|
LIPOSOMAL PERORAL ANTIVIRAL TREATMENT-AND-PROPHYLACTIC AGENT ON BASIS OF HUMAN INTERFERON ALPHA | 2008 |
|
RU2361572C1 |
ENCAPSULATED LYPOSOMAL ANTIVIRAL AGENT BASED ON HUMAN INTERFERON ALPHA-2b FOR VAGINAL APPLICATION | 2014 |
|
RU2552851C1 |
METHOD OF PRODUCING LIPOSOMAL COSMETIC SERUM IN DRY LYOPHILIZED FORM FOR FACE, NECK AND CLEAVAGE SKIN CARE | 2023 |
|
RU2825130C1 |
LIPOSOMAL INTERFERON INDUCER | 2004 |
|
RU2306936C2 |
COSMETIC FACE MASK FILM FOR FACE SKIN CARE WITH VITAMINS IN LIPOSOMES | 2019 |
|
RU2715231C1 |
LIPOSOMAL ANTIVIRAL DRUG FOR ORAL USING | 1996 |
|
RU2123328C1 |
ANTIVIRAL MEDICINAL PREPARATION | 2003 |
|
RU2255735C2 |
LIPOSOMAL AGENT FOR TREATING CHRONIC ATROPHIC GASTRITIS | 2019 |
|
RU2724021C1 |
COMPOSITION OF AQUEOUS SOLUTION OF RECOMBINANT HUMAN INTERFERON ALPHA-2 FOR RECTAL ADMINISTRATION | 2014 |
|
RU2564951C1 |
DOSAGE FORM OF SPECIFIC IMMUNOBIOLOGICAL MEDICINE FOR TREATING AND PREVENTING HIV INFECTION AND PREPARATION METHOD THEREOF | 2014 |
|
RU2600031C2 |
Authors
Dates
2021-04-12—Published
2020-07-27—Filed